Skip to main content

Table 1 Summary of the study population

From: Calmodulin levels in blood cells as a potential biomarker of Alzheimer’s disease

 

Number

Age

Gender

 

Mean

Age range

Male

Female

Lymphoblasts

     

HC

33

64 ± 13

(31 to 83)

12

21

MCI

8

73 ± 6

(62 to 82)

4

4

AD

     

 Total

35

75 ± 7

(59 to 90)

16

19

 Mild

18

76 ± 6

(60 to 83)

8

10

 Moderate

10

76 ± 7

(59 to 84)

4

6

 Severe

7

73 ± 10

(60 to 90)

4

3

FTD

7

64 ± 6

(54 to 70)

0

7

DLB

4

73 ± 15

(58 to 91)

3

1

PD

20

69 ± 10

(49 to 83)

14

6

ALS

10

63 ± 10

(47 to 79)

6

4

PSP

5

79 ± 6

(72 to 85)

1

4

Peripheral blood mononuclear cells

     

HC

15

68 ± 8.3

(57 to 81)

4

11

MCI

7

68 ± 7.6

(55 to 76)

4

3

AD

     

 Total

21

77 ± 9

(58 to 88)

9

12

 Mild

10

73 ± 9

(60 to 85)

5

5

 Moderate

10

79 ± 8

(58 to 86)

4

6

 Severe

1

88

88

0

1

  1. Values expressed as mean ± standard deviation. HC, healthy control individuals, no sign of neurological disease; MCI, patients with a diagnosis of mild cognitive impairment; AD, patients with a diagnosis of probable Alzheimer’s disease; FTD, frontotemporal dementia individuals carrying a loss-of-function PGRN mutation; DLB, patients diagnosed for dementia with Lewy bodies; PD, patients with probable Parkinson’s disease; ALS, patients with a diagnosis of amyotrophic lateral sclerosis; PSP, patients diagnosed of progressive supranuclear palsy.